comparemela.com

Latest Breaking News On - Base genomics - Page 7 : comparemela.com

2 Cathie Wood Picks That Can Become Bigger Winners Than Tesla

ARK Fintech Innovation ETF and the ARK Next Generation Internet ETF. The digital payment company s share price soared in 2020 after the coronavirus pandemic forced people to rapidly transition from an in-person to an online way of life. Although the stock fell almost 30% from its all-time high during the February tech sell-off, it now seems to be on a path of recovery. The digital payments market was estimated to be worth $58.3 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 19.4% from 2021 to 2028. Considering the huge opportunity unfolding, PayPal s offerings in areas such as peer-to-peer payments, cashless payments for online and offline purchases, and credit have been in huge demand. In fact, the company recorded 72.7 million new accounts and reached a total of 377 million in 2020, and total payment volume (TPV) jumped by 31% year over year to $936 billion. PayPal aims to increase active accounts to 750 million and TPV to $2.8 trillion by 202

Madison-based Exact Sciences broadens scope in cancer diagnostics

SHELLEY K. MESCH When Exact Sciences moved to Madison from Boston in 2009, the company had 20 employees and the intention of developing a colon cancer screening test. Now, millions of people are screened each year using Exact Sciences’ Cologuard, the company employs more than 5,000 people, and multiple tests are in development for various types and aspects of cancer. In the last three years, Exact Sciences has broadened its diagnostic abilities by acquiring several companies and purchasing the exclusive use of a testing technology that can detect cancer. The acquired products, both in commercial use and in development, range from screening for cancer, determining the best course of treatment for a cancer patient, and testing blood for recurring cancer.

(ARKG), (ARKK) - 2 Genomic Stocks That Ark Funds Highlighted On Investor Day

Share: Ark Funds hosted an investor webinar Tuesday, sharing ideas on several industries and portfolio components, including a discussion on some names in the genomics space. Ark Funds On Genomics: Ark Funds is well-known for its bullish thesis on the genomics market. The company has the Ark Genomic Revolution ETF (BATS: ARKG), an ETF devoted to the growth of the segment. Exact Sciences (NASDAQ: EXAS) was highlighted by Ark Funds analyst Simon Barnett. The company has made a series of acquisitions that could help the company’s position in the market, he said.  “Incorporating it all together, Exact can broaden out their portfolio [and] determine market share.”  

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.